Arrowhead Pharmaceuticals vs Incyte
Arrowhead Pharmaceuticals (ARWR) and Incyte (INCY) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $5.85B
- Last close
- $41.37
- 12 months
- +8.6%
- Market value
- $23.4B
- Last close
- $114.63
- 12 months
- +12.6%
At a glance
- The biggest part of Incyte's revenue is JAKAFI, 60% of the total in its last annual report.
- By market value, Incyte ($23.4B) is about 4.0 times Arrowhead Pharmaceuticals ($5.8B).
- Over the last 12 months Arrowhead Pharmaceuticals's share price moved +8.6% and Incyte's +12.6%; against the S&P 500 that is +2.9 points and +6.9 points.
- In their last fiscal years Arrowhead Pharmaceuticals kept -160.6% of revenue as net income and Incyte 25.0%.
- In the last 90 days insiders reported 0 open-market purchases at Arrowhead Pharmaceuticals and 0 at Incyte; members of Congress disclosed 0 trades in Arrowhead Pharmaceuticals and 0 in Incyte.
- Next results: Arrowhead Pharmaceuticals Feb 3, 2027, Incyte Feb 8, 2027.
How each one makes money: Arrowhead Pharmaceuticals revenue · Incyte revenue
Share prices on one chart
Arrowhead Pharmaceuticals and Incyte, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Arrowhead Pharmaceuticals ARWRNASDAQ · Biotechnology | Incyte INCYNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $5.85B | $23.4B |
| Revenue, last fiscal year | $451M | $5.14B |
| Net income, last fiscal year | −$724M | $1.29B |
| Net marginNet income as a share of revenue | -160.6% | 25.0% |
| Free cash flow | −$284M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Incyte against
Common questions
How is Arrowhead Pharmaceuticals different from Incyte?
Arrowhead Pharmaceuticals (ARWR) is in Biotechnology on NASDAQ, with $451M of revenue in its last fiscal year and a net margin of -160.6%. Incyte (INCY) is in Biotechnology on NASDAQ, with $5.14B of revenue in its last fiscal year and a net margin of 25.0%. The biggest part of Incyte's revenue is JAKAFI, 60% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Arrowhead Pharmaceuticals and Incyte compare in size?
Incyte has the larger market value: Arrowhead Pharmaceuticals $5.85B and Incyte $23.4B, at the last close.
Whose share price rose more over the last 12 months, ARWR or INCY?
Over the last 12 months Arrowhead Pharmaceuticals moved +8.6% and Incyte +12.6%. Past price moves say nothing about the future.
Which has had more insider buying, Arrowhead Pharmaceuticals or Incyte?
Since 2006, Incyte insiders reported 503 open-market purchases against 26 for Arrowhead Pharmaceuticals. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ARWR or INCY?
In the last 12 months, members of Congress disclosed 0 trades in Arrowhead Pharmaceuticals (ARWR) and 0 in Incyte (INCY).
When did insiders last buy ARWR and INCY?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Arrowhead Pharmaceuticals pageIncyte pageRare insider trades this weekAll comparisons
https://oqro.io/compare/arwr-vs-incy







